Johnson & Johnson (NYSE:JNJ) Shares Acquired by Advisors Asset Management Inc.

Advisors Asset Management Inc. increased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 151,260 shares of the company's stock after acquiring an additional 6,566 shares during the period. Advisors Asset Management Inc.'s holdings in Johnson & Johnson were worth $24,513,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Briaud Financial Planning Inc grew its position in Johnson & Johnson by 8.7% during the 3rd quarter. Briaud Financial Planning Inc now owns 1,253 shares of the company's stock valued at $203,000 after purchasing an additional 100 shares during the last quarter. Sachetta LLC raised its position in Johnson & Johnson by 11.8% in the 3rd quarter. Sachetta LLC now owns 7,599 shares of the company's stock worth $1,232,000 after buying an additional 802 shares during the last quarter. Segall Bryant & Hamill LLC purchased a new stake in Johnson & Johnson in the third quarter worth approximately $5,883,000. Prospera Private Wealth LLC grew its position in Johnson & Johnson by 948.6% in the 3rd quarter. Prospera Private Wealth LLC now owns 52,293 shares of the company's stock worth $8,475,000 after purchasing an additional 47,306 shares during the period. Finally, Premier Fund Managers Ltd bought a new position in shares of Johnson & Johnson during the 3rd quarter valued at $7,982,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Up 0.1 %

Shares of Johnson & Johnson stock traded up $0.09 during trading on Wednesday, hitting $153.10. The stock had a trading volume of 9,060,825 shares, compared to its average volume of 7,028,536. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The stock has a market cap of $368.59 billion, a PE ratio of 22.09, a PEG ratio of 2.74 and a beta of 0.53. The firm's fifty day simple moving average is $160.83 and its 200-day simple moving average is $156.19.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analysts' expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm's quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the business earned $2.66 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.24%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson's dividend payout ratio is presently 71.78%.

Insider Buying and Selling at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the company's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company's stock, valued at $3,131,683.38. This represents a 22.90 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have issued reports on JNJ. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, September 14th. Morgan Stanley increased their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 16th. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Daiwa America cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 23rd. Finally, Wolfe Research initiated coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an "outperform" rating and a $190.00 price target for the company. Seven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $175.94.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.